LOGIN  |  REGISTER

Mettler-Toledo Announces Webcast of Presentation at the BofA Securities 2023 Healthcare Conference

April 10, 2023 | Last Trade: US$1,248.96 9.92 -0.79

Columbus, OH, April 10, 2023 (GLOBE NEWSWIRE) -- Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 10:40am Pacific Time (1:40pm Eastern Time).  To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at www.mt.com/investors.  

METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.   

    


Recursion

Stock Quote

Last Trade: US$1,248.96
Daily Change: -9.92 -0.79
Daily Volume: 24,393
Market Cap: US$26.350B

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB